Allergan and Novartis to collaborate on new NASH therapy trials
Allergan is set to expand its research and development programme on non-alcoholic steatohepatitis (NASH) through a partnership with Novartis that will test a new combination therapy approach for the condition. The pharmaceutical firms have signed a clinical trial agreement under which Novartis will carry out a Phase IIb study testing Allergan’s cenicriviroc (CVC), a once-daily,